New hope for hard-to-treat lymphoma: targeted drug combo tested in large trial

NCT ID NCT04224493

Disease control Sponsor: Epizyme, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 6 times

Summary

This study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the standard therapy alone. About 600 adults will take part, and the study is currently active but not recruiting new participants.

Why investors are watching

Ipsen S.A., a micro-cap company, owns Epizyme, Inc., which runs this Phase 3 trial of tazemetostat combined with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. The trial stopped early after an urgent safety measure, so the remaining data are descriptive, not confirmatory. For a small company, this readout matters because tazemetostat is a key drug candidate, and the outcome will shape its value.

If it works: If the descriptive results show that tazemetostat helps patients live longer without their disease worsening, Ipsen could gain a stronger position in treating follicular lymphoma. A positive signal might support further development or regulatory discussions, which would matter for a company of this size.

If it fails: The trial already stopped treatment and enrollment due to a safety measure, which raises the risk that the drug has serious side effects or lacks benefit. If the descriptive data show no clear advantage over placebo, or if safety concerns persist, Ipsen may face a setback in its pipeline and investor confidence could weaken.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

599 people

The number who actually took part.

Started

Jun 2020

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have voluntarily agreed to provide written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol. 2. Males or females are ≥18 years of age, or per country adult legal age regulations, at the time of providing voluntary written informed consent. 3. Life expectancy ≥3 months before enrollment. 4. Meet requirement for hepatitis and human immunodeficiency virus (HIV) infection as follows * Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic hepatitis B virus (HBV) infection Note: Participants whose HBV infection status could not be determined by serologic test results have to be negative for HBV-DNA by PCR to be eligible for study participation. Participants seropositive for HBV with undetectable HBV DNA by PCR are permitted with appropriate antiviral prophylaxis. * Negative test results for hepatitis C virus (HCV) Note: Participants who are positive for HCV antibody must be negative for HCV RNA by PCR to be eligible for study participation * If HIV positive, HIV infection is controlled. Based on Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections - Guidance for Industry (https://www.fda.gov/media/121319/download), patients with HIV should be considered eligible if they have CD4+ T-cell counts ≥ 350 cells/uL and in general, if they have not had an opportunistic infection within the past 12 months. Other exclusion criteria should be considered regarding the drug-drug interaction if antiviral drugs are used. Therefore, in case of controlled HIV infection, since antiviral drugs are used, trial patients should be on established ART for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrolment. 5. Have histologically confirmed FL, Grades 1 to 3A. 6. Must have been previously treated with at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy: a. Systemic therapy includes treatments such as: i. Rituximab monotherapy ii. Chemotherapy given with or without rituximab iii. Radioimmunoconjugates such as 90Y-ibritumomab tiuxetan and 131I-tositumomab. b. Systemic therapy does not include, for example: i. Local involved field radiotherapy for limited-stage disease ii. Helicobacter pylori eradication c. Prior investigational therapies will be allowed provided the subject has received at least 1 prior systemic therapy as discussed in Inclusion Criterion #6a. d. Prior autologous/allogeneic hematopoietic stem cell transplant (HSCT) will be allowed. e. Prior chimeric antigen receptor T-cell therapy (CAR T) will be allowed. 7. Must have documented relapsed, refractory, or PD after treatment with systemic therapy (refractory defined as less than PR or disease progression \<6 months after last dose). 8. Have measurable disease as defined by the Lugano Classification (Cheson, 2014; Appendix 5). 9. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. 10. Within 7 days prior to randomization, all clinically significant toxicity related to a prior anticancer treatment (ie, chemotherapy, immunotherapy, and/or radiotherapy must have either resolved to Grade 1 per NCI CTCAE Version 5.0 OR are clinically stable and no longer clinically significant. 11. Have provided sufficient tumor tissue block or unstained slides for EZH2 mutation testing in all subjects to allow for stratification a. If EZH2 mutation status is known from site-specific testing, subjects can be enrolled. Tumor tissue will be required for confirmatory testing of EZH2 status at study-specific laboratories. If the archival tumor sample was collected more than 24 months prior to the anticipated administration of the first dose (cycle 1 day 1), then a fresh biopsy must be provided. Fresh tumor biopsy is appropriate except for procedures deemed to result in unacceptable risk because of the anatomical location including brain, lung/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel. Archival tumor biopsy sections mounted on slides are also acceptable. NOTE: Confirmatory testing will also be performed for Stage 1, if local EZH2 testing is conducted, unless there is insufficient tumor tissue to perform testing after discussion with the Sponsor's or Designee Medical Monitor. 12. Time between prior anticancer therapy and first dose of tazemetostat as follows: 1. Cytotoxic chemotherapy - At least 21 days. 2. Noncytotoxic chemotherapy (eg, small molecule inhibitor) - At least 14 days. 3. Nitrosoureas - At least 6 weeks. 4. Monoclonal and/or bispecific antibodies or CAR T - At least 28 days. 5. Radiotherapy - At least 6 weeks from prior radioisotope therapy; at least 12 weeks from 50% pelvic or total body irradiation. 13. Adequate renal function defined as calculated creatinine clearance ≥30 mL/minute per the Cockcroft and Gault formula. 14. Adequate bone marrow function: a. Absolute neutrophil count (ANC) ≥1000/mm3 (≥1.0 × 10\^9/L) if no lymphoma infiltration of bone marrow OR ANC ≥750/mm3 (≥75 × 10\^9/L) with bone marrow infiltration * Without growth factor support (filgrastim or pegfilgrastim) for at least 14 days. b. Platelets ≥75,000/mm3 (≥75 × 10\^9/L) * Evaluated at least 7 days after last platelet transfusion. c. Hemoglobin ≥9.0 g/dL * May receive transfusion 15. Adequate liver function: 1. Total bilirubin ≤1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome. 2. Alkaline phosphatase (ALP) (in the absence of bone disease), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN if subject has liver infilration). 16. International normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (aPTT) ≤1.5 × ULN (unless on warfarin, then INR ≤3.0). In subjects with thromboembolism risk, prophylactic anticoagulation, or antiplatelet therapy at investigator discretion is recommended. 17. Females of childbearing potential (FCBP) must have a negative urine or serum pregnancy tests (beta-human chorionic gonadotropin \[β-hCG\] tests with a minimum sensitivity of 25 mIU/mL or equivalent units of β-hCG) at screening within 10 to 14 days prior to first dose of study drug. The subject may not receive study drug until the study doctor has verified that the results of pregnancy tests are negative. All females will be considered to be of childbearing potential unless they are naturally postmenopausal (at least 24 months consecutively amenorrhoeic \[amenorrhea following cancer therapy does not rule out childbearing potential\] and without other known or suspected cause) or have been sterilized surgically (ie, total hysterectomy and/or bilateral oophorectomy, with surgery completed at least 1 month before dosing). 18. Females of childbearing potential (FCBP) enrolled must either practice complete abstinence or agree to use two reliable methods of contraception simultaneously. This includes ONE highly effective method of contraception and ONE additional effective contraceptive method. Contraception must begin at least 28 days prior to first dose of study drug, continue during study treatment (including during dose interruptions), and for 12 months after study drug discontinuation. Female subjects must also refrain from breastfeeding for 12 months following last dose of study drug. If the below contraception methods are not appropriate for the FCBP, she must be referred to a qualified contraception provider to determine the medically effective contraception method appropriate for the subject. The following are examples of highly effective and additional effective methods of contraception: Examples of highly effective methods: * Intrauterine device (IUD) * Hormonal (ovulation inhibitory combined \[estrogen and progesterone\] birth control pills or intravaginal/transdermal system, injections, implants, levonorgestrel-releasing intrauterine system \[IUS\], medroxyprogesterone acetate depot injections, ovulation inhibitory progesterone-only pills \[e.g. desogestrel\]) NOTE: There is a potential for tazemetostat interference with hormonal contraception methods due to enzymatic induction. * Bilateral tubal ligation * Partner's vasectomy (if medically confirmed \[azoospermia\] and sole sexual partner). Examples of additional effective methods: * Male latex or synthetic condom, * Diaphragm, * Cervical Cap NOTE: Female subjects of childbearing potential exempt from these contraception requirements are subjects who practice complete abstinence from heterosexual sexual contact. True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or post ovulation methods) and withdrawal are not acceptable methods of contraception. 19. All study participants enrolled must be registered into the applicable pregnancy prevention program (e.g. REVLIMID REMS in the US, Pregnancy Prevention Programme \[PPP\] in Europe) for lenalidomide to be administered and be willing and able to comply with the requirements of the applicable program as appropriate for the country in which the drug is being used. a. Female subjects of childbearing potential (FCBP) must adhere to the scheduled pregnancy testing as required in theapplicable pregnancy prevention program. During study treatment, FCBP must agree to have pregnancy testing weekly for the first 28 days of study participation and then every 28 days for FCBP with regular or no menstrual cycles OR every 14 days for FCBP with irregular menstrual cycles. FCBP must also have a pregnancy test at end of lenalidomide treatment, at day 14 (for FCBP with irregular menstrual cycles) and day 28 following the last dose of lenalidomide and at overall treatment discontinuation (at the End-of-Treatment/30-day safety Follow-up visit). Female subjects exempt from this requirement are subjects who have been naturally postmenopausal for at least 24 consecutive months OR are surgically sterilized (ie, total hysterectomy or bilateral oophorectomy) with surgery at least 1 month before the first dose of study treatment. 20. Male subjects must either practice complete abstinence or agree to use a latex or synthetic condom, even with a successful vasectomy (medically confirmed azoospermia), during sexual contact with a pregnant female or FCBP from first dose of study drug, during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation. NOTE: Male subjects must not donate semen or sperm from first dose of study drug, during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation. Exclusion Criteria: All Subjects 1. Prior exposure to tazemetostat or other inhibitor(s) of EZH2. 2. Prior exposure to lenalidomide or drugs of the same class. 3. Grade 3b, mixed histology, or FL that has histologically transformed to diffuse large B-cell lymphoma (DLBCL) (subjects transformed from DLBCL to FL may be enrolled). 4. Has thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE Version 5.0 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN). 5. Has a prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) or B-cell acute lymphoblastic leukemia (B-ALL). 6. Subjects with uncontrolled leptomeningeal metastases or brain metastases or history of previously treated brain metastases. 7. Subjects taking medications that are known strong CYP3A inhibitors and strong or moderate CYP3A inducers (including St. John's wort). 8. Are unwilling to exclude grapefruit juice, Seville oranges, and grapefruits from the diet and/or consumed within 1 week of the first dose of study drug and for the duration of the study. 9. Major surgery within 4 weeks before the first dose of study drug. a. Note: Minor surgery (eg, minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 3 weeks prior to enrollment. 10. Are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat. 11. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia. 12. Prolongation of corrected QT interval using Fridericia's formula (QTcF) to ≥480 msec at screening or history of long QT syndrome. 13. Venous thrombosis or pulmonary embolism within the last 3 months before starting tazemetostat. a. Note: Participants who have experienced deep vein thrombosis/pulmonary embolism more than 3 months before enrollment are eligible but are recommended to receive prophylaxis. 14. Have an active infection requiring systemic therapy. 15. Known hypersensitivity to any component of tazemetostat or lenalidomide; known severe hypersensitivity to any component of rituximab requiring hospitalization or resuscitation. 16. Active viral infection with or seropositive for HBV: HBV surface antigen (HBsAg) positive OR HBsAg negative, anti-HBs positive and/or anti-HBc positive with detectable HBV DNA. NOTE: Subjects who are HBsAg negative, anti-HBs positive and/or anti-HBc positive, but with undetectable viral DNA and normal ALT are eligible. Subjects who are seropositive due to HBV vaccination (HBsAg negative, HBV surface antibody \[anti-HBs\] positive, and HBV core antibody \[anti-HBc\] negative) are eligible. 17. Active viral infection with hepatitis C virus (as measured by positive HCV antibody and detectable viral RNA, HIV), or known active infection with human T-cell lymphotropic virus. NOTE: Subjects with a history of hepatitis C infection (HCV antibody reactive) who have normal ALT and undetectable HCV RNA are eligible. 18. Any other medical or social condition that, in the Investigator's judgment, will interfere with a participant's ability to provide informed consent, to receive study drugs, or meet study demands, or that substantially increases the risk associated with the subject's participation in the study, or that may interfere with interpretation of results. 19. Female subjects who are pregnant or lactating/breastfeeding. 20. Subjects who have undergone a solid organ transplant. 21. Subjects with malignancies other than FL. a. Exception: Subjects with another malignancy who have been disease-free for 3 years, or subjects with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Follicular lymphoma Refractory follicular lymphoma Relapsed/refractory follicular lymphoma

Contacts and locations

Locations

AOU Careggi

Florence, Firenze, 50134, Italy
AOU Federico II

Naples, Campania, 80122, Italy
ASST Spedali Civili di Brescia

Brescia, 25123, Italy
Ajou University Hospital

Suwon, South Korea
Ankara University Medical Faculty - Hematology

Ankara, Turkey (Türkiye)
Arizona Oncology Associates - Tuscon-Rusadill Road

Tucson, Arizona, 85704, United States
Association Hospital de Caridade de Iju

Ijuí, Brazil
Astera Cancer Care

East Brunswick, New Jersey, 08816, United States
Astera Cancer Center

East Brunswick, New Jersey, 08816, United States
Azienda Ospedaliera Ordine Mauriziano di Torino, Ospedale Umberto I di Torino

Torino, Italy
Azienda Ospedaliera Santa Maria di Terni

Terni, Terni, 05100, Italy
Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), Ospedale Maggiore

Trieste, Italy
BRCR Medical Center, INC

Plantation, Florida, 33322, United States
Barwon Health, University Hospital Geelong

Geelong, Victoria, 3220, Australia
Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
Buddihist Tzu Chi Medical Foundation- Hualien Tzu Chi Hospital

Hualien City, Taiwan
C.H. de Navarra

Pamplona, Spain
CHRU Brest Hôp Morvan

Brest, Brittany Region, 29609, France
CHRU de Besançon- Hopital Jean Minjoz

Besançon, 25000, France
CHRU de Lille Hop Claude Huriez

Lille, Nord, 59037, France
CHU de Clermont-Ferrand, site Estaing

Clermont-Ferrand, 63000, France
CHU de Grenoble - Hopital Albe

La Tronche, Isere, 38700, France
CHU de Limoges Dupuytren

Limoges, Haute-Vienne, 87042, France
CHU de Nancy Brabois

Vandœuvre-lès-Nancy, 54511, France
CHU de Nantes - Hematologie

Nantes, Loire-Atlantique, 44000, France
Cancer Specialists of North Florida

Fleming Island, Florida, 32003, United States
Catholic University Of Sacred Heart

Roma, 00168, Italy
Centre Henri Becquerel

Rouen, Haute-Normandie, 76038, France
Centre Hosp Mulh Hop Emile Muller

Mulhouse, Haut-Rhin, 68100, France
Centre Hospitalier - Hôpital de jour d'Hématologie

Périgueux, France
Centre Hospitalier Bretagne Atlantique

Vannes, 56017, France
Centre Hospitalier Docteur Schaffner

Lens, France
Centre Hospitalier Le Mans

Le Mans, Sarthe, 72000, France
Centre Hospitalier Universitaire D'Angers - Hématologie Clinique

Angers, France
Centre Hospitalier Universitaire de Bordeaux-Hopital du Haut Leveque

Pessac, Aquitaine, 33600, France
Centre Hospitalier Universitaire de Poitiers

Poitiers, France
Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, H2X 3E4, Canada
Centrum Medyczne Pratia Poznan

Skórzewo, Greater Poland Voivodeship, 60-185, Poland
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology

Kaohsiung City, 833, Taiwan
Clínica Universidad de Navarra

Madrid, Spain
Columbia U - Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
Debreceni Egyetem Klinikai Központ

Debrecen, Hajdú-Bihar, 4032, Hungary
Diakoneo Diak Schwaebisch Hall gGmbH

Schwäbisch Hall, Baden-Wurttemberg, 74523, Germany
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research

Ankara, Turkey (Türkiye)
FirstHealth of the Carolinas

Pinehurst, North Carolina, 28374, United States
Flinders Medical Centre

Bedford Park, South Australia, 5042, Australia
Florida Cancer Affiliates/Ocala Oncology - Clinic

Ocala, Florida, 34474, United States
Florida Cancer Specialists

St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists & Research Institute (FCS) - Atlantis

West Palm Beach, Florida, 33401, United States
Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center

Fort Myers, Florida, 33908, United States
Florida Cancer Specialists - Panhandle

Tallahassee, Florida, 32308, United States
Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China
Fundacao Antonio Prudente - Hospital A.C.Camargo Cancer Center

São Paulo, Brazil
Gabrail Cancer Center Research

Canton, Ohio, 44718, United States
Gachon University Gil Medical Center

Incheon, South Korea
Gazi University Medical Faculty

Ankara, Turkey (Türkiye)
GenesisCare - St Andrew's

Adelaide, Australia
Gold Coast University Hosptial

Southport, Australia
H Lee Moffitt Cancer Center and Research Institute I

Tampa, Florida, 33612, United States
HC-UFG - Hospital das CLINICAS da Universidade Federal de Go

Goiânia, Brazil
Hematology Oncology Associates of Rockland, P.C.

Nyack, New York, 10960, United States
Henan Cancer Hospital

Zhengzhou, Henan, 45008, China
Henan Provincial People's Hospital

Zhengzhou, Henan, 450008, China
Hollywood Private Hospital

Nedlands, Western Australia, 6009, Australia
Hopital Henri Mondor - Hemopathies Lymphoides

Créteil, Île-de-France Region, 94010, France
Hopital Saint Louis

Paris, Paris, 75010, France
Hospital Alemao Oswaldo Cruz (HAOC)

São Paulo, Brazil
Hospital Costa del Sol

Marbella, Málaga, 29603, Spain
Hospital Del Mar

Barcelona, Barcelona, 08003, Spain
Hospital Haroldo Juacaba - Instituto do Cancer do Ceara

Ceará, Brazil
Hospital Santa Cruz

Curitiba, Brazil
Hospital Univ. Infanta Leonor

Madrid, Madrid, 28031, Spain
Hospital Universitari Vall d'Hebrón

Barcelona, Cataluny, 08035, Spain
Hospital Universitario La Paz

Madrid, Madrid, 28046, Spain
Hospital Universitario Nuestra Señora de Valme

Seville, Sevilla, 41014, Spain
Hospital Universitario Virgen De La Macarena

Seville, Spain
Hospital Universitario de Salamanca

Salamanca, 37007, Spain
Hospital Virgen de la Arrixaca

El Palmar, Spain
Hospital de Clinicas de Porto Alegre - Centro de Pesquisa Clinica

Porto Alegre, Brazil
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Huntsman Cancer Institute; The University of Utah

Salt Lake City, Utah, 84112, United States
IEO - Istituto Europeo di Oncologia, IRCCS

Milan, Italy
Illinois Cancer Specialists

Niles, Illinois, 60714, United States
Imperial College Healthcare NHS Trust - Hammersmith Hospital

London, London City, W12 0HS, United Kingdom
Institut Bergonie

Bordeaux, Gironde, 33000, France
Institut Gustave Roussy

Villejuif, France
Instituto D'Or de Pesquisa e Ensino- Recife

Recife, Brazil
Instituto D'or de Pesquisa e Ensino

São Paulo, Brazil
Instituto Nacional de Câncer - INCA

Rio de Janeiro, Brazil
Instituto de Oncologia e Hematologia - HEMOMED

São Paulo, Brazil
Instituto de Psiquiatria - UFRJ

Rio de Janeiro, Brazil
Irmandade Santa Casa de Misericordia de Sao Paulo

São Paulo, Brazil
Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS

Meldola, Forli-Cesena, 47014, Italy
Jiangxi Cancer Hospital

Nanchang, China
Kliniken Maria Hilf GmbH

Mönchengladbach, North Rhine-Westphalia, 41063, Germany
Klinikum Der Universität München AöR

München, Bavaria, 81377, Germany
L'Hôpital Privé Confluent

Nantes, 44202, France
L'hôpital Privé du Concluent

Nantes, France
Levine Cancer Institute - Concord

Concord, North Carolina, 28205, United States
Liga Norte Riograndense Contra o Cancer

Natal, Brazil
MICS Centrum Medyczne Torun

Torun, 87-100, Poland
MTZ Clinical Research powered by Pratia

Warsaw, Poland
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic - Rochester

Rochester, Minnesota, 55901, United States
Mays Cancer Center

San Antonio, Texas, 78229, United States
Medipol Bagcilar Mega Hospital

Istanbul, Turkey (Türkiye)
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
Messino Cancer Center

Asheville, North Carolina, 28806, United States
Millennium Physicians - Oncology

Houston, Texas, 77090, United States
Monash Health

Clayton, Victoria, 3168, Australia
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

Warsaw, Masovian Voivodeship, 02-781, Poland
National Cancer Center Singapore

Singapore, Singapore
National Cheng Kung University Hospital

Tainan, Tainan, 704, Taiwan
National Taiwan University Hospital

Taipei, Taiwan
New Mexico Cancer Care Alliance

Albuquerque, New Mexico, 87131-0001, United States
Northwick Park Hospital Middlesex, United Kindgom, HA1 3UJ

Middlesex, United Kingdom
Nova Scotia Health Centre for Clinical Research

Nova Scotia, Canada
Oncology Hematology Care (OHC), Inc. - Kenwood Office

Cincinnati, Ohio, 45236, United States
Oncology and Hematology Associates of Southwest Virginia Inc.

Roanoke, Virginia, 24014, United States
Ondokuz Mayis University Medical Faculty - Hematology

Samsun, Turkey (Türkiye)
Országos Onkológiai Intézet

Budapest, Budapest, 1122, Hungary
Ospedale Civile S.Spirito, PO di Pescara, AUSL Pescara

Pescara, Italy
Ospedale Infermi di Rimini, AUSL Rimini, Distretto di Rimini, Presidio di Rimini, Santarcangelo di Romagna e Novafeltria

Rimini, Italy
Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda

Milan, Italy
Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy
Ospedale S.Giacomo Apostolo, PO Castelfranco Veneto, AULSS 2 Marca Trevigiana

Treviso, Italy
Ospedale San Gerardo, ASST di Monza

Monza, Italy
Ospedale Vito Fazzi, ASL Lecce

Lecce, Italy
PO Garibaldi-Nesima, ARNAS Garibaldi

Catania, 95122, Italy
PU Campus Bio-Medico di Roma

Roma, Italy
Peking University Third Hospital

Beijing, 100191, China
Peninsula Health - Frankston

Frankston, Australia
Pratia MCM Krakow

Krakow, 30-727, Poland
Pratia Onkologia Katowice

Katowice, Poland
Pusan National University Hospital

Busan, South Korea
Regina Elena, Istituto Nazionale dei Tumori , IFO, IRCCS

Roma, Italy
Regional Cancer Care Associates LLC - Little Silver

Little Silver, New Jersey, 07739, United States
Regional Cancer Care Associates-Freehold

Freehold, New Jersey, 07728, United States
Regional Medical Oncology Center

Wilson, North Carolina, 27895, United States
Rocky Mountain Cancer Centers (RMCC) - Boulder

Boulder, Colorado, 80303, United States
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital

Cornwell, United Kingdom
Royal Hobart Hospital

Hobart, Australia
Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 20025, China
Samsung Medical Center

Seoul, Seoul Teugbyeolsi [Seoul-T'Ukp, 06351, South Korea
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Semmelweis Egyetem Általános Orvostudományi Kar

Budapest, Budapest, 1088, Hungary
Seoul National University Hospital

Seoul, Seoul Teugbyeolsi, 03080, South Korea
Severance Hospital, Yonsei University Health System

Seoul, Seoul Teugbyeolsi [Seoul-T'Ukp, 03722, South Korea
Shandong Cancer Hospital

Shandong, China
Shanxi Bethune Hospital

Taiyuan, Shanxi, 30032, China
Sichuan Provincial People's Hospital

Sichuan, China
Sir Mortimer B Davis/Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Southern Cancer Center

Mobile, Alabama, 36608, United States
St Bartholomew's Hospital Barts Health NHS Trust

London, London, City of, EC1A 7BE, United Kingdom
St. Joseph Mercy Hospital

Ypsilanti, Michigan, 48197, United States
St. Mary's Hospital and Regional Medical Center - St. Mary's

Grand Junction, Colorado, 81501, United States
Städt. Krankenhaus Kiel

Kiel, Schleswig-Holstein, 24116, Germany
Sunnybrook Health Sciences Centre Odette Cancer Centre

Ottawa, Canada
TOI - Clinical Research

Cerritos, California, 90703, United States
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
Tan Tock Seng Hospital

Singapore, Singapore
Texas Oncology

Plano, Texas, 75075, United States
Texas Oncology - Amarillo

Amarillo, Texas, 79124, United States
Texas Oncology - Medical City Dallas Pediatric Hematology

Dallas, Texas, 75230, United States
Texas Oncology- Weslaco

Weslaco, Texas, 78596, United States
Texas Oncology-Austin Midtown

Austin, Texas, 78705, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, 550004, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266071, China
The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, Seoul Teugbyeolsi [Seoul-T'Ukp], 06591, South Korea
The Clatterbridge Cancer Centre NHS Foundation Trust - Clatterbridge Cancer Centre

Bebington, United Kingdom
The First Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, 361003, China
The First Bethune Hospital of Jilin University

Changchun, Jinlin, 130021, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050011, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Zhejiang, Hangzhou, 310000, China
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Tianjin Medical University Cancer Institute & Hospital

Tianjin, 300060, China
Tongji Hospital of Tongji Medical College of HUST

Hangzhou, China
Tongji Hospital of Tongji University

Shanghai, China
UC San Diego Health Sciences

La Jolla, California, 92093, United States
UCLA Clinical Research Unit Hematology/Oncology

Santa Monica, California, 90404, United States
UCSF Fresno

Clovis, California, 93611, United States
USO Texas Oncology - Tyler

Tyler, Texas, 75702, United States
UT Health East Texas HOPE Cancer Center - Tyler

Tyler, Texas, 75701, United States
UZ Leuven - Campus Gasthuisberg

Leuven, Vlaams Brabant, 3000, Belgium
Universitaetsklinikum Bonn AöR

Bonn, North Rhine-Westphalia, 53127, Germany
Universitair Ziekenhuis Gent

Ghent, Oost-Vlaanderen, 9000, Belgium
University Health Network Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
University Medical Center Schleswig Holstein

Kiel, Germany
University Of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States
Universitätsmedizin Mainz

Mainz, Hesse, 55131, Germany
Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu

Wroclaw, 50-367, Poland
Utah Cancer Specialists/ IHO Corp

Salt Lake City, Utah, 84106, United States
Virginia Cancer Specialists

Gainesville, Virginia, 22155, United States
Vivantes Klinikum am Urban Hämatologie und Onkologie

Berlin, Germany
Weill Cornell Medicine-New York Presbyterian Hospital

New York, New York, 10021, United States
Western General Hospital - Haematology

Edinburgh, Edinburgh, City of, EH4 2XU, United Kingdom
Western Pennsylvania Hospital Hematology & Cellular Therapy

Pittsburgh, Pennsylvania, 15524, United States
Wheeling Hospital

Wheeling, West Virginia, 26003, United States
Willamette Valley Cancer Institute and Research Center - Oncology

Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.